Media.Player

Avain Beta-defensin analogues as therapeutic and food preservative agents

Detailed Technology Description

None

Others

*Abstract

The current invention developed at the University of Missouri presents a unique set of beta-defensin peptide analogues for use as alternatives for antibiotics. These peptides were custom synthesized to enhance their broad spectrum antimicrobial properties as anti-infective therapeutics, food preservation agents, and vaccine adjuvants. These beta-defensin analogues are novel antimicrobials with different resistance profiles compared to existing antibiotics that could help combat pathogens that are becoming increasingly resistant to existing antibiotic therapeutics.Antimicrobial resistance poses a major issue to global public health and the economy, as excessive misuse of antibiotics in medicine and food production are contributing to a rise in the number of drug resistant pathogens. New antimicrobials are in ever increasing demand to combat this issue. The antibiotics market is huge, with an expected growth to $57 billion by 2024. According to MarketsandMarkets, the estimated market size for antibiotic alternatives in animal feeds alone is expected to exceed $3 billion by 2019. The antimicrobial spray market is also experiencing growth as more doctors and hospitals are turning to these as cleaning agents. With the growing resistance to existing antibiotics and the decline in the discovery and development of new antibiotics, alternatives to antibiotics, such as these beta-defensin analogues, will continue to capture a growing share of the antibiotics market.Potential Areas of Applications• Novel therapeutic agents as alternatives to conventional antibiotics• Antimicrobial sprays• Vaccine adjuvants• Food preservativesMain Advantages of Invention• Broad spectrum antimicrobial properties• Different resistance profile than commercially available antibiotics and products• Custom syntheticsSTATE OF DEVELOPMENT: On-going microbial testing for broad spectrum analysis; utilizing a skin infectivity model of lead candidatesLICENSING POTENTIAL:Seeking licensee with the potential to continue research and commercializePATENT STATUS: Patent Application FiledTECHNOLOGY INNOVATORS: Shuping Zhang, Ming YangTECHNOLOGY MANAGER CONTACT:Samuel E. Bish, PhD; bishs@missouri.edu; 573-882-5016

*Principal Investigator

Name: Shuping Zhang, Professor

Department:

Name: Ming Yang, Graduate Assistant

Department:

Country/Region

USA